Clinical studies

/sg/cardiovascular/dabigatran-etexilate/prescribing-information/prescribing-information-praxbind

Prescribing Information for Praxbind®
/sg/cardiovascular/dabigatran-etexilate/prescribing-information/prescribing-information-pradaxa

Prescribing Information for Pradaxa®
/sg/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-trial-results

RE-DUAL PCI™ trial - Results
/sg/cardiovascular/dabigatran-etexilate/reversibility/life-happens-100629

Life Happens
/sg/oncology/giotrif/sequencing/sequential-afatinib-and-osimertinib-patients-egfr-mutation-positive

Publication: GioTag Final Analysis
/sg/metabolic/empagliflozin/cv-risk-protection/emprise®-new-data-release-ada-congress-2020

EMPRISE® New Data Release in ADA Congress 2020
/sg/metabolic/empagliflozin/cv-risk-protection/how-did-empagliflozin-kick-start-transformation

How did empagliflozin kick-start the transformation of guidelines?
/sg/oncology/giotrif/efficacy/giotrif-delays-onset-risk-cns-progression

GIOTRIF® delays onset and risk of CNS progression in patients with or without brain metastases
/sg/oncology/giotrif/efficacy/giotrif-vs-gefitinib-1st-line-treatment-egfrm-nsclc

GIOTRIF® vs gefitinib for 1st-line treatment of EGFRm+ NSCLC
/sg/oncology/giotrif/efficacy/giotrif-provides-3-years-long-term-response

GIOTRIF® provides ≥3 years long-term response even with dose modification
/sg/metabolic/empagliflozin/cv-risk-protection/how-did-empagliflozin-kick-start

How Did Empagliflozin Kick-Start the Transformation of Guidelines?
/sg/cardiovascular/telmisartan/prescribing-information/telmisartan-amlopidine-twynsta-prescribing

Telmisartan + Amlopidine (Twynsta®) Prescribing Information
/sg/cardiovascular/telmisartan/prescribing-information/telmisartan-hctz-micardis-plus-prescribing

Telmisartan + HCTZ (Micardis Plus®) Prescribing Information
/sg/cardiovascular/telmisartan/prescribing-information/telmisartan-micardis-prescribing-information

Telmisartan (Micardis®) Prescribing Information
/sg/cardiovascular/telmisartan/organ-protection/twynsta-micardis-inside-effective-against-progression

Twynsta, with Micardis inside, is effective against progression of renal disease in hypertensive patients with type 2 diabetes
/sg/metabolic/empagliflozin/cv-risk-protection/empagliflozin-cardiovascular-benefits-lead

Empagliflozin's cardiovascular benefits lead the change in T2D treatment paradigm
/sg/metabolic/empagliflozin/experts-interview/diabetes-and-ramadhan-practical-guidelines-using-sglt2

Diabetes and Ramadhan - Practical Guidelines in Using SGLT2 Inhibitors
/sg/metabolic/empagliflozin/cv-risk-protection/empa-reg-outcome-breakthrough-trial-type-2-diabetes

EMPA-REG OUTCOME: A breakthrough trial in type 2 diabetes
/sg/oncology/giotrif/safety/xerosis-management

AE management in focus: Xerosis
/sg/oncology/giotrif/safety/stomatitis-management

AE management in focus: Stomatitis
/sg/oncology/giotrif/safety/scalp-lesion-management

AE management in focus: Scalp lesion
/sg/oncology/giotrif/safety/strategies-optimise-management-egfr-tki-related-side-effects

Strategies to optimise the management of EGFR  TKI-related side effects
/sg/oncology/giotrif/efficacy/real-world-evidence-giotrif-efficacy

Real-world evidence: GIOTRIF® efficacy in Taiwan and Korea
/sg/oncology/giotrif/efficacy/pre-clinical-and-clinical-activity-giotrif

Pre-clinical and clinical activity of GIOTRIF® in uncommon EGFR mutations
/sg/oncology/giotrif/safety/ae-management-focus-diarrhoea

AE management in focus: Diarrhoea
/sg/oncology/giotrif/safety/ae-management-focus-paronychia

AE management in focus: Paronychia
/sg/oncology/giotrif/safety/ae-management-focus-skin-rash

AE management in focus: Skin Rash
/sg/oncology/giotrif/dosing-and-administration/giotrif-maintains-efficacy-despite

GIOTRIF® maintains efficacy despite dose modification
/sg/metabolic/empagliflozin/cv-risk-protection/emprise-empagliflozin-real-world-effectiveness

EMPRISE - Empagliflozin Real World Effectiveness
/sg/metabolic/empagliflozin/experts-interview/asian-forum-2018-how-have-recent-cv-outcome-trials-transcript

Asian CardioDiabetes Forum 2018 - How have recent CV outcome trials influence clinical practice by Dr. Neale Cohen (transcript)
/sg/metabolic/empagliflozin/experts-interview/asian-forum-2018-role-cardiologist-transcript

Asian CardioDiabetes Forum 2018 - The role of a cardiologist in diabetes management by Dr. Mansoor Husain (transcript)
/sg/metabolic/linagliptin/prescribing-information/trajenta-duo-prescribing-information

Linagliptin + Metformin HCl (Trajenta Duo®) Prescribing Information
/sg/metabolic/linagliptin/prescribing-information/trajenta-prescribing-information

Linagliptin (Trajenta®) Prescribing Information
/sg/oncology/giotrif/sequencing/sequential-treatment-afatinib

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell-lung cancer: an observational study
/sg/metabolic/empagliflozin/experts-interview/asian-forum-2018-why-it-important-examine-evidence-transcript

Asian CardioDiabetes Forum 2018 - Why is it important to examine evidence and not assume class effect by Prof. Richard Donnelly (transcript)
/sg/respiratory/spiolto/tovito/tovito-phase-iii-clinical-trial-programme

TOVITO® Clinical Trial Programme
/sg/respiratory/spiolto/prescribing-information

Spiolto® Respimat® Prescribing Information
/sg/oncology/giotrif/efficacy/south-korea-real-world-data

South Korea Real World Data
/sg/oncology/giotrif/prescribing-information

Afatinib (Giotrif®) Prescribing Information
/sg/metabolic/empagliflozin/prescribing-information/jardiance-duo-prescribing-information

Jardiance Duo® Prescribing Information
/sg/metabolic/empagliflozin/prescribing-information/jardiance-prescribing-information

Jardiance® Prescribing Information
Load more